Astria Therapeutics (NASDAQ:ATXS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report released on Tuesday, Benzinga reports. The firm currently has a $16.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Astria Therapeutics’ Q3 2024 earnings at ($0.47) EPS, Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($1.82) EPS, FY2025 earnings at ($1.80) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($1.99) EPS and FY2028 earnings at ($1.68) EPS.

ATXS has been the topic of a number of other research reports. Wedbush reissued an outperform rating and issued a $22.00 price objective on shares of Astria Therapeutics in a report on Friday, May 10th. TD Cowen initiated coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They set a buy rating and a $35.00 price target on the stock. Finally, Oppenheimer reduced their price objective on Astria Therapeutics from $29.00 to $25.00 and set an outperform rating for the company in a research note on Tuesday, May 21st. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Astria Therapeutics presently has a consensus rating of Buy and a consensus target price of $25.20.

Astria Therapeutics Trading Up 10.9 %

Shares of ATXS opened at $11.07 on Tuesday. The firm has a fifty day simple moving average of $10.12 and a two-hundred day simple moving average of $11.37. The firm has a market cap of $607.89 million, a PE ratio of -4.77 and a beta of 0.73. Astria Therapeutics has a 1-year low of $4.26 and a 1-year high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). As a group, research analysts forecast that Astria Therapeutics will post -1.62 EPS for the current fiscal year.

Institutional Trading of Astria Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Quest Partners LLC boosted its holdings in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,112 shares during the period. Ameritas Investment Partners Inc. boosted its stake in shares of Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 2,861 shares during the period. AJOVista LLC purchased a new stake in shares of Astria Therapeutics during the fourth quarter worth about $51,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Astria Therapeutics during the first quarter worth about $200,000. Finally, Panagora Asset Management Inc. bought a new stake in Astria Therapeutics during the 4th quarter valued at approximately $119,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.